Alnylam Pharmaceuticals, Inc.
US ˙ NasdaqGS ˙ US02043Q1076

SecurityALNY / Alnylam Pharmaceuticals, Inc.
InstitutionAIA Group Ltd
Latest Disclosed Ownership7,742 shares
Latest Disclosed Value $ 2,561,596
AIA Group Ltd reports 61.63% decrease in ownership of ALNY / Alnylam Pharmaceuticals, Inc.

On May 6, 2026 - AIA Group Ltd filed a 13F-HR form disclosing ownership of 7,742 shares of Alnylam Pharmaceuticals, Inc. (US:ALNY) valued at $2,561,596 USD as of March 31, 2026. The entity filed a previous 13F-HR on February 9, 2026 disclosing 20,177 shares of Alnylam Pharmaceuticals, Inc.. This represents a change in shares of -61.63% during the quarter. The current value of the position is $2,265,154 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-05-06 2026-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 7,742 -12,435 -61.63 2,562 -68.08 0.0372
2026-02-09 2025-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 20,177 -13,136 -39.43 8,023 -47.18 0.1201
2025-12-18 2025-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 33,313 3,081 10.19 15,191 54.09 0.2685
2025-08-06 2025-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 30,232 3,741 14.12 9,858 37.82 0.2144
2025-05-12 2025-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 26,491 3,643 15.94 7,153 33.05 0.1757
2025-02-12 2024-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 22,848 -5,369 -19.03 5,376 -30.72 0.1299
2024-10-31 2024-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 28,217 8,789 45.24 7,761 64.37 0.2003
2024-07-31 2024-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 19,428 4,784 32.67 4,721 115.77 0.1381
2024-05-06 2024-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 14,644 0 0.00 2,189 -21.94 0.0714
2024-01-31 2023-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 14,644 0 0.00 2,803 8.10 0.1150
2023-11-01 2023-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 14,644 2,050 16.28 2,593 8.40 0.1266
2023-07-28 2023-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 12,594 6,910 121.57 2,392 110.19 0.1158
2023-04-28 2023-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 5,684 685 13.70 1,139 -4.21 0.0617
2023-01-31 2022-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 4,999 1,075 27.40 1,188 51.34 0.0724
2022-11-04 2022-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 3,924 1,039 36.01 785 86.46 0.0514
2022-08-11 2022-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 2,885 2,885 421 0.0226
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.